Comparative Pharmacology
Head-to-head clinical analysis: LARYNG O JET KIT versus LIDOCAINE HYDROCHLORIDE 0 1 AND DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARYNG O JET KIT versus LIDOCAINE HYDROCHLORIDE 0 1 AND DEXTROSE 5 IN PLASTIC CONTAINER.
LARYNG-O-JET KIT vs LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine, a local anesthetic, stabilizes neuronal membranes by inhibiting sodium ion channels, blocking initiation and conduction of nerve impulses. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor activation, reducing systemic absorption of lidocaine and prolonging local effect.
Lidocaine is a sodium channel blocker, which stabilizes neuronal membranes and inhibits the initiation and conduction of nerve impulses. Dextrose 5% provides caloric support.
Topical administration via laryngeal spray: 1-2 sprays (10-20 mg) to the larynx and pharynx, repeated as needed up to every 1-2 hours, not to exceed 8 sprays per 24 hours.
Intravenous: 50-100 mg bolus (1-2 mg/kg) over 2-3 minutes, followed by continuous infusion at 1-4 mg/min (20-50 mcg/kg/min). Total maximum dose: 300 mg over 1 hour.
None Documented
None Documented
Terminal elimination half-life is 1.5–2 hours (mean 1.8 h), necessitating frequent dosing for sustained effect.
Terminal elimination half-life: 1.5–2.0 hours in adults with normal hepatic function. In patients with hepatic impairment or heart failure, half-life may be prolonged (>3 hours). Clinical context: short half-life requires continuous infusion for sustained antiarrhythmic effect.
Renal excretion of unchanged drug accounts for approximately 70% of elimination, with 30% undergoing hepatic metabolism and biliary/fecal elimination.
Renal: approximately 10% unchanged; hepatic metabolism to 4-hydroxy-2,6-xylidine and glycylxylidide, which are excreted renally. Total renal excretion of metabolites and parent drug accounts for >95% of the dose. Fecal excretion is minimal (<5%).
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)